LATEST
Gaza Mother Gives Birth After Israeli Airstrike Killed All Three of Her ChildrenICE-Tech Backs New Research to Help Shape the Future of Pet Insurance and Animal WelfarePotentiaMetrics Appoints Healthcare Innovator Marcus Thygeson, MD, MPH, as Chief Medical OfficerUS Sanctions Plan Threatens ICC as UN Findings on Gaza GrowGaza’s Children Face Deafness After Israeli Bombardment, as Deaths and Injuries MountGladia to Join OVH Groupe, Accelerating Europe’s Sovereign Voice AI AmbitionsWorld Services Group Elects 2026–2027 Board of DirectorsCharlotte Heath Crowned Champion Of The Fourth Edition Of La Sella Open‘A Self-Destruction Strategy’: Richard Wolff Warns Israel Could Bring About Its Own DemiseTwenty Thousand Names on a Shroud: Gaza's Dead Children Brought Before the WorldGaza Mother Gives Birth After Israeli Airstrike Killed All Three of Her ChildrenICE-Tech Backs New Research to Help Shape the Future of Pet Insurance and Animal WelfarePotentiaMetrics Appoints Healthcare Innovator Marcus Thygeson, MD, MPH, as Chief Medical OfficerUS Sanctions Plan Threatens ICC as UN Findings on Gaza GrowGaza’s Children Face Deafness After Israeli Bombardment, as Deaths and Injuries MountGladia to Join OVH Groupe, Accelerating Europe’s Sovereign Voice AI AmbitionsWorld Services Group Elects 2026–2027 Board of DirectorsCharlotte Heath Crowned Champion Of The Fourth Edition Of La Sella Open‘A Self-Destruction Strategy’: Richard Wolff Warns Israel Could Bring About Its Own DemiseTwenty Thousand Names on a Shroud: Gaza's Dead Children Brought Before the World
Business

ProMIS Neurosciences Announces Closing of US $7.4 Million Private Placement

Richard Powell  3 min read

ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic misfolded proteins implicated in the development of neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that it has closed a fully subscribed private placement of 1,383,755 Units of the Company at a price of US$5.40 per Unit for gross proceeds of US$7,472,277.  Each Unit is comprised of one Common Share of the Company and one quarter of one Common Share purchase Warrant. Each full Warrant is exercisable for one Common Share at US$7.50 for a period of five years commencing six months from the closing of the Offering.

  ProMIS’ lead product candidate, PMN310, is a novel monoclonal antibody that is highly selective for toxic oligomers of amyloid-beta which are found in brains of AD patients. ProMIS believes specific targeting of toxic misfolded proteins may directly address fundamental AD pathology while potentially leading to enhanced efficacy and safety compared to other agents due to reduction of off-target activity. ProMIS’ pipeline also includes PMN267, an antibody against misfolded TDP-43 for ALS, and PMN442 targeting misfolded toxic forms of alpha-synuclein, a driver of MSA.     “This is an exceptionally exciting time in Alzheimer’s research,” stated Gail Farfel, Ph.D., Chief Executive Officer of ProMIS. “Our patented platform technology has created an antibody candidate, PMN310, specific to toxic misfolded oligomers known to be present in Alzheimer’s disease, which we believe may have greater therapeutic potential than other agents due to reduction of off-target activity. We plan to initiate our first-in-human study in 2023, subject to FDA’s acceptance of our IND, which will represent a significant milestone for the Company, for our shareholders, and for the Alzheimer’s community.”   “ProMIS anticipates submission of an IND application for PMN310 by year-end 2022,” added Eugene Williams, Chairman and Co-Founder.  “We are excited to be in a position to capitalize on the recent positive momentum in the Alzheimer’s field and grateful for the continued support of our investors. In the future, we look forward to advancing additional programs with our antibody candidates for ALS, PMN267, and for MSA, PMN442, both of which were created using our proprietary platform to generate antibodies highly selective for toxic misfolded proteins.”    

Ceros Financial Services, Inc. acted as the exclusive placement agent for the sale of Units (the “Placement Agent”). In consideration for the services performed, the Company paid Placement Agent a cash fee equal to 8% of the gross proceeds from the Offering and issued the Placement Agent and its designees placement agent warrants to purchase an aggregate of 69,188 Common Shares. Each placement agent warrant entitles the holder thereof to purchase one Common Share at a price of $6.10 per share for a period of five years commencing six months from the closing of the private placement.

  The Units were offered by a Placement Agent pursuant to an applicable prospectus exemption under Ontario securities laws and pursuant to exemptions from registration under applicable United States federal and state securities laws.  The securities sold in the Offering will be “restricted securities” under applicable United States federal and state securities laws. Closing of the Offering remains subject to the final approval of the Toronto Stock Exchange.   This press release shall not constitute an offer to sell, the solicitation of an offer to buy or sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been registered under the United States Securities Act of 1933, as amended (or applicable state securities laws), and such securities may not be offered or sold absent registration or an applicable exemption from such registration requirements.

 

ProMIS Neurosciences Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on Nasdaq and the TSX under the symbol PMN.

 

http://www.promisneurosciences.com

Related articles

Top